Podcasts

E-Books

Videos

Articles

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability.

A Closer Look at New FDA Guidance Removing Barriers to Biosimilar Development

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

BioRationality: The FDA Sets Sights on Removing Clinical Efficacy Studies for Biosimilars

Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for chronic conditions and oncology.

Biosimilars Improve Health System Resilience in Latin American, Caribbean Nations

A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane, supporting cost-effective healthcare solutions.

Data Confirm Biosimilar Ranibizumab Non-Inferiority as Myopic CNVM Treatment

Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter disease duration, and female sex.

Later-Line Therapies Drive Biosimilar Prescriptions in Turkish Rheumatology Practices

A new study reveals Stivant, a bevacizumab biosimilar, matches Avastin in safety and efficacy for treating retinopathy of prematurity in infants.

Biosimilar Bevacizumab Matches Avastin in Treating Retinopathy of Prematurity

The FDA has approved Celltrion's Eydenzelt, a new aflibercept biosimilar, enhancing treatment options for retinal diseases in the US.

FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions.

Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.

Review Identifies Gaps in Evidence on Biosimilar DMARD Use During Pregnancy

The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market entries enhancing patient care.

All News